Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
Mar 16, 2026Today, a brief rundown of news from Sarepta Therapeutics and Sana Biotechnology, as well as updates from Bayer, Inovio and Unnatural Products that you may have missed. Sarepta Therapeutics has begun evaluating new safeguards meant to reduce the risk of liver damage in certain people who receive Elevidys, its Duchenne muscular dystrophygenetherapy. Last year, two teenagers with Duchenne and ...
source: https://www.biopharmadive.com